Fulltext

Examination of the effect of acute levodopa administration on the loudness dependence of auditory evoked potentials (LDAEP) in humans

Hitz, K. ; Heekeren, K. ; Obermann, C. ; Huber, T. ; Juckel, G. ; Kawohl, W.

In: Psychopharmacology, 2012, vol. 221, no. 3, p. 389-396

Ajouter à la liste personnelle
    Titre
    • Examination of the effect of acute levodopa administration on the loudness dependence of auditory evoked potentials (LDAEP) in humans
    Auteur
    • Hitz, K.. Department of General Social Psychiatry, University of Zurich, Zurich, Switzerland
    • Heekeren, K.. Department of General Social Psychiatry, University of Zurich, Zurich, Switzerland
    • Obermann, C.. Department of General Social Psychiatry, University of Zurich, Zurich, Switzerland
    • Huber, T.. Internal Medicine, Psychiatric University Hospital Zurich, Zurich, Switzerland
    • Juckel, G.. Department of Psychiatry, Ruhr-University Bochum, Bochum, Germany
    • Kawohl, W.. Department of General Social Psychiatry, University of Zurich, Zurich, Switzerland
    Type de document
    • Postprint
    Identifiant OAI-PMH
    • oai:doc.rero.ch:319199
    Summary
    Rationale: The loudness dependence of the auditory evoked potential (LDAEP) is considered a noninvasive in vivo marker of central serotonergic functioning in humans. Nevertheless, results of genetic association studies point towards a modulation of this biomarker by dopaminergic neurotransmission. Objective: We examined the effect of dopaminergic modulation on the LDAEP using L-3,4-dihydroxyphenylalanine (levodopa)/benserazide (Madopar®) as a challenge agent in healthy volunteers. Methods: A double-blind placebo-controlled challenge design was chosen. Forty-two healthy participants (21 females and 21 males) underwent two LDAEP measurements, following a baseline LDAEP measurement either placebo or levodopa (levodopa 200mg/benserazide 50mg) were given orally. Changes in the amplitude and dipole source activity of the N1/P2 intensities (60, 70, 80, 90, and 100dB) were analyzed. Results: The participants of neither the levodopa nor the placebo group showed any significant LDAEP alterations compared to the baseline measurement. The test-retest reliability (Cronbachs Alpha) between baseline and intervention was 0.966 in the verum group and 0.759 in the placebo group, respectively. Conclusions: The administration of levodopa showed no effect on the LDAEP. These findings are in line with other trials using dopamine receptor agonists